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Abstract
Background: Chronic Myeloid Leukemia (CML) is a malignant pluripotent stem cells disorder of myeloid cells. In
CML patients, polymorphonuclear leukocytes (PMNL) the terminally differentiated cells of myeloid series exhibit
defects in several actin dependent functions such as adhesion, motility, chemotaxis, agglutination, phagocytosis
and microbicidal activities. A definite and global abnormality was observed in stimulation of actin polymerization in
CML PMNL. Signalling molecules ras and rhoGTPases regulate spatial and temporal polymerization of actin and
thus, a broad range of physiological processes. Therefore, status of these GTPases as well as actin was studied in
resting and fMLP stimulated normal and CML PMNL.
Methods: To study expression of GTPases and actin, Western blotting and flow cytometry analysis were done,
while spatial expression and colocalization of these proteins were studied by using laser confocal microscopy. To
study effect of inhibitors on cell proliferation CCK-8 assay was done. Significance of differences in expression of
proteins within the samples and between normal and CML was tested by using Wilcoxon signed rank test and
Mann-Whitney test, respectively. Bivariate and partial correlation analyses were done to study relationship between
all the parameters.
Results: In CML PMNL, actin expression and its architecture were altered and stimulation of actin polymerization
was absent. Differences were also observed in expression, organization or stimulation of all the three GTPases in
normal and CML PMNL. In normal PMNL, ras was the critical GTPase regulating expression of rhoGTPases and actin
and actin polymerization. But in CML PMNL, rhoA took a central place. In accordance with these, treatment with
rho/ROCK pathway inhibitors resulted in specific growth inhibition of CML cell lines.
Conclusions: RhoA has emerged as the key molecule responsible for functional defects in CML PMNL and
therefore can be used as a therapeutic target in CML.
Keywords: Chronic Myeloid Leukemia (CML), Actin, RhoGTPases, Polymorphonuclear leukocytes (PMNL), n-formyl-
methionyl-leucyl-phenylalanine (fMLP), Signal transduction
Background
Chronic myeloid leukemia (CML) is characterized by the
presence of Philadelphia (Ph
1) chromosome bearing chi-
meric bcr-abl gene that translates a protein p210 which
has increased and unregulated tyrosine kinase activity [1].
Polymorphonuclear leukocytes (PMNL) are terminally
differentiated myeloid cells that play a crucial role in host
defence by migrating to the sites of infection and elimi-
nating foreign bodies. This complex process involves a
cascade of signalling events that results in sequential sti-
mulation of chemotaxis, phagocytosis, degranulation and
oxidative burst. PMNL from CML patients exhibit
defects in several actin dependent functions such as
motility, chemotaxis, adhesion, aggregation, endocytosis,
microbicidal activities and polymerization of actin per se
[2]. Bcr-abl has an actin-binding domain that enhances
its transforming ability. Targets of bcr-abl are similar to
the major components of signal transduction pathways
leading to actin polymerization. These include ras, PI3K,
MAPK, JNK/SAPK, NF-kB and STAT. Ras and other
oncoproteins require active rhoGTPases to elicit their
transforming activities [3]. RhoGTPases also regulate
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any medium, provided the original work is properly cited.spatial localization of F-actin. Since ras and rhoGTPases
play significant role in actin polymerization and cell
transformation, to understand their role in the pathogen-
esis of CML, the present study is focused on the status of
these GTPases and actin in normal and CML PMNL.
The results suggest a significant role of rhoA in func-
tional defects of CML PMNL and identify rhoA as a ther-
apeutic target in CML.
Results
A classical chemoattractant - n-formyl-methoinyl-leucyl-
phenyl alanine (fMLP) binds to its receptors on PMNL
and initiates a cascade of signalling pathways that leads
to various morphological, biochemical and functional
events. On exposure to fMLP, PMNL show polarization
[4]. Polarization of PMNL is associated with polymeriza-
tion of actin that occurs in two phases - rapid rise in F-
actin that peaks around 10-15 sec and decays after a
half time of 30 sec and a second phase which decays
after about 3 min. Various actin dependent events such
as release of Ca
+2, cell polarization, cell motility and
chemotaxis are initiated in the first phase, while phago-
cytosis and oxidative burst are observed later. Therefore,
polymerization of actin and status of rhoGTPases were
studied after fMLP stimulation, at early time points - 0.5
and 5 min and later time points - 10, 30, 45 and 60 min.
CML PMNL do not show classical morphological
responses
Unstimulated normal PMNL were round (Figure 1a). After
fMLP stimulation for 0.5 min, 90% of PMNL showed
either blebbing or classical oriented cells with lamellipodia
and uropod (Figure 1b). At 5 min, the cells became elon-
gated and later they rounded up. Unstimulated CML
PMNL were round (Figure 1c). At early time points of
fMLP stimulation, in about 45% of samples, 50% cells
showed fine peripheral projections (Figure 1d). Classical
lamellipodia and uropod formation was rare. With increas-
ing time the cells rounded up. Thus, CML PMNL exhib-
ited lack of morphological responses towards fMLP.
Actin expression is lower and stimulation of actin
polymerization is absent in CML PMNL
Western blot analysis would estimate expression of total
actin i.e., G plus F actin in the cells. In normal PMNL, at
early time points of fMLP stimulation, 60% of the normal
samples showed a drop in total actin as compared to that
in unstimulated PMNL (Figure 2a). The total actin
reduced significantly by 20% and 36% after 5 and 45 min
Figure 1 Morphology of PMNL: Phase contrast micrographs
showing morphology of a) unstimulated and b) fMLP stimulated
(0.5 min) normal PMNL. Arrows indicate classical morphology of
oriented cells showing lamellipodia and uropods. c) Unstimulated
and d) fMLP stimulated (0.5 min) CML PMNL.
Figure 2 Time kinetics of GTPase and actin stimulation:( a)
Western blot for expression of actin and GTPases - ras, rac1 and
rhoA: lane 1- unstimulated control, lane 2- fMLP 0.5 min, lane 3-
fMLP 5 min, lane 4- fMLP 10 min, lane 5- fMLP 30 min and lane 6-
fMLP 45 min in normal (n = 14) and CML PMNL (n = 22); For ras
and rac1 both the patterns of expression, i.e., 21 kd alone or 21 kd
along with 25 kd are depicted. (b-e) Representative FCM plots for
expression of F-actin and GTPases- Ras, rac1 and rhoA in normal (n
= 14) and CML PMNL (n = 22): i) isotype, s) secondary control, a)
unstimulated, b) fMLP 0.5 min, c) fMLP 5 min, d) fMLP 10 min, e)
fMLP 30 min, and f) fMLP 45 min.
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Page 2 of 13of fMLP stimulation, respectively (Table 1a). In CML
PMNL, 50% of the samples showed a slight drop in total
actin during early time points of fMLP stimulation (Figure
2a). The average total actin dropped significantly (15%) at
0.5 and 45 min of fMLP stimulation (Table 1a). Though
unstimulated and fMLP-stimulated normal PMNL showed
higher levels of total actin as compared to the levels in the
respective CML PMNL, this difference was not statistically
significant.
Flow cytometry (FCM) analysis showed that on fMLP
stimulation for 0.5 min, F-actin in normal PMNL
increased significantly (range 1.1 - 3.5 fold) (Figure 2b).
This was followed by a drop and then a second increase.
Since the time frame for this second response varied
from sample to sample, the average of the median fluor-
escence did not show considerable change (Table 1b). In
CML, only 25% samples showed an increase in F-actin
after 0.5 min of stimulation that was comparable to that
in normal PMNL (Figure 2b). Overall, F-actin levels
were steady in fMLP stimulated CML PMNL (Table 1b).
Thus, CML PMNL showed defective stimulation of actin
polymerization.
Organization of F-actin is altered in CML PMNL
Unstimulated normal PMNL showed F-actin as weak
cytoplasmic and bright peripheral fluorescence. At 0.5
Table 1 Quantitation of GTPases and actin expression
a) Densitometric analysis of Western blots of GTPases - ras, rac1 and rhoA, and actin in normal and CML PMNL
Protein PMNL Unstimulated fMLP stimulation
0.5 min 5 min 10 min 30 min 45 min
Actin Normal 52.89
± 10.55
42.89
± 9.01
42.22
± 9.48 $
46.67
± 8.90
42.44
± 10.23
34.22
± 8.61 $
CML 39.50
± 8.74
32.70
± 7.58 $
35.80
± 9.04
37.50
± 8.44
32.30
± 8.47
33.00
± 9.09 $
Ras Normal 37.80
± 9.11
41.00
± 8.05
46.71
± 6.52
52.43
± 9.61
58.29
± 8.60 $
59.79
± 10.66 $
CML 37.37
± 8.90
41.10
± 12.65
46.31
± 13.52
45.37
± 12.60
46.04
± 12.00 #
47.72
± 13.93
Rac 1 Normal 58.22
± 9.47
67.29
± 9.30
70.64
± 8.1
63.00
± 9.58
60.21
± 8.58
49.21
± 7.44
CML 63.05
± 11.33
69.90
± 9.11
81.17
± 11.47 $
82.36
± 11.21 $
75.77
± 9.57 $
65.14
± 9.77
Rho A Normal 62.71
± 12.45
65.14
± 15.15
49.64
± 10.88
43.36
± 11.46 $
38.31
± 10.79 $
24.75
± 7.44
CML 97.18
± 14.24
94.27
± 12.61
78.14
± 11.09
78.19
± 10.59 #
75.59
± 9.99 #
78.00
± 12.01 $#
b) Median fluorescence channels in flow cytometric estimation of GTPases - ras, rac1 and rhoA, and F-actin in normal and CML PMNL
Protein PMNL Unstimulated fMLP stimulation
0.5 min 5 min 10 min 30 min 45 min
F-Actin Normal 28.53
± 3.19
36.79
± 2.43 $
32.64
± 2.48
34.39
± 2.06
30.52
± 3.54
26.64
± 3.44
CML 22.75
± 2.09
23.42
± 2.29 #
20.58
± 1.92 #
20.01
± 1.89 #
23.97
± 3.12
24.65
± 3.34
Ras Normal 122.21
± 24.83
133.14
± 17.94
180.49
± 8.65 $
179.18
± 4.86 $
169.19
± 26.33
183.75
± 27.48
CML 99.86
± 9.76
103.51
± 13.76
102.38
± 12.88#
117.40
± 17.25 #
115.69
± 15.40
126.65
± 16.27 $
Rac 1 Normal 176.62
± 20.81
225.95
± 46.83
186.68
± 30.36
194.79
± 30.48
199.84
± 29.24
217.03
± 25.76
CML 190.82
± 19.64
118.94
± 10.18 $
129.79
± 13.71 $
132.73
± 12.81 $
170.33
± 22.15
158.16
± 17.09 $#
Rho A Normal 84.45
± 11.65
82.77
± 10.91
67.84
± 6.92
72.79
± 7.20
72.63
± 10.34
65.71
± 8.58
CML 73.83
± 11.33
60.68
± 10.14
61.33
± 10.95
62.74
± 11.41
76.22
± 13.57
76.33
± 12.97
Values represent Mean ± S.E.M.; Normal - n = 14 and CML - n = 22; $ = significantly different as compared to the unstimulated control; # = significantly different
as compared to the respective normal PMNL.
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Page 3 of 13min of stimulation, an increase in F-actin along with cell
polarization was seen. F-actin was concentrated in blebs
or lamellipodia and uropods (Figure 3a). With increasing
time, the pattern of F-actin distribution was similar to
that seen in the unstimulated cells. Changes in F-actin
levels observed by laser scanning confocal microscope
(LCM) were similar to those seen using FCM. In unsti-
mulated CML PMNL, F-actin was seen as weak cyto-
plasmic and slightly brighter peripheral fluorescence.
After fMLP treatment, though morphological changes
were observed in some cells, F-actin picture remained
unaltered (Figure 3a).
Actin provides structural framework and defines cell
shape and polarity. Its dynamic properties provide the
driving force for the cells to move and divide. Changes
in its expression could alter G to F polymerization
dynamics. Defects in actin could be at the level of
expression or polymerization. Alterations within actin
Figure 3 (a) F-actin and rhoA localization: Middle Z planes of LCM images showing transmission images (upper panel) and distribution of F-
actin (middle panel) and rhoA (lower panel) in unstimulated normal and CML PMNL and those stimulated with fMLP (0.5 min); U - Uropod, L -
Lamellipodia, P - Projection. (b) Proposed model for interactions between GTPases and F-actin: (i) Unstimulated and (ii) fMLP stimulated normal
PMNL; (iii) unstimulated and (iv) fMLP stimulated CML PMNL. Bold font indicates crucial regulatory molecules.
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regulatory signaling proteins or actin binding proteins.
Altered actin expression and polymerization is known to
be associated with cancer [5]. In normal and CML
PMNL, basal levels of total actin and F-actin were not
significantly different. On fMLP treatment, total actin
levels decreased in both, but normal PMNL showed sig-
nificant increase in F-actin, indicating that the total
actin expression remained above the critical levels and
hence actin could polymerize. Tarachandani et al have
shown that in CML PMNL, actin expression, though
lower, was sufficient for polymerization [6]. Hence, lack
of stimulation of actin polymerization and altered F-
actin architecture in CML PMNL could be due to
defects in signalling leading to defective actin polymeri-
zation. The signalling molecules - rhoGTPases, play an
important role in the spatial and temporal organization
of actin. Ras, the major target of bcr-abl, activates
rhoGTPases. In the present studies, on fMLP stimula-
tion CML PMNL showed filopodia-like but thin projec-
tions, suggesting involvement of rhoA. This finding was
different from that in normal PMNL where lamellipodia
formation indicative of rac signaling were seen [7]. Since
rhoA and rac govern dynamics and spatial organization
of F-actin differently, changes in actin expression and F-
actin localization, leading to defective functions [4,8] in
CML PMNL, could be due to altered rhoGTPases
regulation.
About 70% of the bcr-abl protein localizes to the cytos-
keleton. This localization is important in cellular trans-
formation. An actin-binding domain of the bcr-abl kinase
enhances its leukemogenicity [9]. Analogously, a muta-
tion in the F-actin binding domain of c-abl reduces its
ability to transform fibroblasts [10]. Constitutively active
bcr-abl alters actin dependent cell adhesion and motility
by phosphorylating actin-binding proteins [11]. Another
mechanism that alters actin functioning in the neoplastic
state targets upstream regulators of actin binding pro-
teins. Ras - the key signalling molecule in the actin poly-
merization pathway, is also a major target of bcr-abl. Ras
regulates cell proliferation pathways that in turn regulate
gene expression, and morphological (or motility) path-
ways controlling the actin cytoskeleton [12]. Therefore,
the GTPases - ras, rho A and rac1 were studied.
Ras expression in CML PMNL is refractory to fMLP
treatment
I nt h em a j o r i t yo fn o r m a la n dC M LP M N L ,as h a r p2 1
kd band was seen for ras in the Western blots (Figure
2a). But 43% of normal and 32% of CML samples
showed an additional band at 25 kd at all the time
points, indicating existence of differential isoprenylation
of ras. For densitometry analysis, both the bands were
considered collectively.
On fMLP stimulation, 50% normal samples showed
increase in ras at early time points. With increasing
time, this percentage increased to 79% resulting in a sig-
nificant increase in ras (about 1.5 fold) at 30 and 45
min (Table 1a). On fMLP stimulation, CML PMNL
showed very little or no change in ras expression (Figure
2a). Normal and CML PMNL expressed similar basal
levels of ras. But after stimulation for 30 min, normal
PMNL showed significantly higher ras levels as com-
pared to the corresponding CML PMNL.
In FCM estimation, normal PMNL showed about two-
fold increase in ras (range 1.35-4.2) after fMLP stimula-
tion (Figure 2c). The increase was significant at 5 and
10 min of fMLP stimulation (Table 1b). In CML PMNL,
the majority of the samples did not show any response
to fMLP. Only at 45 min of stimulation, 36% of the
samples showed increase in ras resulting in a statistically
significant increase (1.2 fold) in average ras expression
(Figure 2c, Table 1b).
Basal ras levels in normal PMNL were slightly higher
than in CML PMNL. But an extremely delayed and low
r e s p o n s eo fC M LP M N Lt of M L Pr e s u l t e di ns i g n i f i -
cantly higher ras levels in normal PMNL, stimulated for
5 and 10 min than the respective CML PMNL. Ham-
mond et al. have suggested that intracellular signalling
could occur through modulation of the oscillations in
response to stimulus. Cancer can result from changes in
the oscillation frequencies, amplitudes and phasings of
signaling molecules [13]. In Dictyostelium discoideum
ras activation stimulates a small amount of preexisting,
membrane-associated PI3K, causing F-actin polymeriza-
tion [14]. Thus, defective ras dynamics might lead to
defective actin polymerization. The present findings
reveal that on fMLP stimulation, ras levels increased
only in normal PMNL, indicating defects in signals reg-
ulating ras expression in CML PMNL.
Intracellular localization of ras in normal and CML PMNL
is comparable
Unstimulated and stimulated normal and CML PMNL
showed diffused cytoplasmic staining for ras. In normal,
bleb formation, observed at 0.5 min of stimulation, was
associated with an increase in ras. The fluorescence
intensity increased with increase in stimulation time,
indicating an increase in ras. Only 50% CML PMNL
that showed morphological changes on stimulation
showed slight increase in ras expression. Overall change
was not noted in the levels of ras in response to stimu-
lation. There was no distinct difference in the localiza-
tion of ras in normal and CML PMNL (Additional file
1: Figure S1 & Additional file 2: Figure S2). Since only
10% of the total GTPase undergoes a transition from
inactive to active state, limitations of the used LCM
technology and lack of specific probe could have made
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in stimulation of actin polymerization could be partly
attributed to alterations in dynamics of ras expression.
The morphological pathway is branched into PI3K-
dependent and PI3K-independent pathways. The PI3K-
dependent pathway also depends on protein kinase C
(PKC) ξ and Akt/PKB, and controls 70-80% of F-actin.
PKCξ is involved in pseudopodia formation and oxida-
tive burst [12,15]. In fMLP stimulated PMNL, transloca-
tion of PKCξ to the plasma membrane started at 1 min,
but peripheral actin polymerization was observed by 30
seconds [4]. This difference in time kinetics suggests
that PKCξ may not have direct role in spatial distribu-
tion of F-actin in PMNL. The PI3K-independent path-
way depends on rhoGTPases, ROCK, src kinases and
NADPH, and is modulated by cAMP [16]. Ras and its
associated rhoGTPases - rac, rho and cdc42, play an
important role in the spatial and temporal organization
of actin, and regulate cell adhesion and motility. Cdc42
is required for cell polarity and rac1 for protrusive activ-
ity [17]. Basal rhoA activity is necessary to maintain cell
adhesion. This pro-adherent effect of rhoA probably
counterbalances the effects of rac1 and Cdc42 as rac1
must inhibit rhoA to exert its activity toward myosin
[18]. Since rhoGTPases cross-activate each other,
balanced control of this activation determines outcomes
like cell polarization, directional motility and substrate
adhesion. As mentioned earlier, CML PMNL showed
defects in cell polarization, adhesion, motility, pinocyto-
sis, etc., and it was suggested that defective actin poly-
merization might have contributed to these defects [19].
In CML, defective actin polymerization may result in
early egress of PMNL and immature myeloid cells from
the bone marrow. Therefore, to understand defective
actin polymerization in CML PMNL further, expression
of GTPases - rac1, and rhoA, was examined.
Different rac1 isoforms are stimulated in normal and CML
PMNL
In the Western blots 50% of normal and 59% CML sam-
ples showed a single band of rac1 at 21 kd, at all the time
points studied (Figure 2a). But the remaining samples
showed two bands, at 21 kd and 25 kd. The 25 kd band
could be of the rac1b protein, as the molecular weight of
recombinant rac1b isolated from E. coli is reported to be
higher than 21 kd [20]. Therefore, for densitometry ana-
lysis, both the bands were considered collectively.
In Western blot studies, about 60% of normal and
CML samples showed increase in rac1 levels at early
time points of fMLP stimulation. Increase in rac1
expression was followed by a drop at later time points
of fMLP stimulation. In normal, this increase was not
significant., but in CML PMNL, increase at 5, 10 and 30
min of fMLP stimulation was statistically significant
(Table 1a). Rac1 levels were comparable in normal and
CML PMNL, under unstimulated and stimulated condi-
tions. But the major responder bands in normal and
CML were 25 kd and 21 kd, respectively. The 25 kd
band could be of rac1b. Rac1b acts like a fast cycling
GTPase [21] and induces formation of lamellipodia in
NIH3T3 [22]. Similarly in normal PMNL too, rac1b
could be responsible for actin polymerization in lamelli-
podia. Though unstimulated CML PMNL showed higher
levels of total rac1, and these levels increased further in
response to stimulation, lower response of rac1b might
have resulted in the absence of lamellipodia in CML
PMNL leading to the absence of chemotaxis.
In FCM studies, only 50% of the normal samples
showed increase in rac1 (range 1.3-2.3) at early time
point, specifically at 0.5 min of fMLP stimulation and
then showed a second increase (Figure 2d). Of the
remaining, 30% samples showed a drop and 20% sam-
ples showed delayed increase in rac1 levels. Hence, the
increase in the average median channel for rac1 on sti-
mulation was statistically insignificant (Table 1b). In
CML PMNL, majority of the samples showed a drop
(range 10- 60%) in rac1 levels on stimulation at early
time points of stimulation followed by a partial recovery.
At later time points, only 21% of the samples showed a
true increase in rac1 levels (Figure 2d). Thus, CML
PMNL showed a significant drop in rac1 levels after 0.5,
5, 10 and 45 min of stimulation (Table 1b). FCM studies
showed higher expression of rac1 in unstimulated CML
PMNL than that in normal PMNL. On fMLP stimula-
tion, the rac1 levels increased in normal PMNL and
dropped in CML PMNL. Hence, significant difference
between rac1 levels of both was seen at 45 min of fMLP
stimulation (Table 1b).
The differences in results, between Western blot and
FCM, could be because the major responder band in the
two populations was different and the antibodies used
have different affinities towards these bands. Secondly,
depending on the localization of the 21 kd and 25 kd
rac1 proteins in the cell, in FCM, the antibody could
have had altered accessibility.
fMLP stimulated transport of rac1 to the cell membrane
is negligible in CML PMNL
In unstimulated normal PMNL, rac1 expression was less
in cytoplasm and more on the membrane. On stimula-
tion, the fluorescence intensity increased, but the distri-
bution pattern of rac1 remained same. In the majority
of unstimulated CML samples rac1 was distributed
everywhere. On fMLP treatment, rac1 distribution
remained unaltered. In both, changes in rac1 levels seen
by LCM matched with that observed by FCM, and were
independent of morphological changes (Additional file
3: Figure S3 & Additional file 4: Figure S4).
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between normal and CML PMNL was that normal
PMNL showed a higher concentration of rac1 on the
membrane, suggesting that CML PMNL could be defec-
tive in translocation of rac1 to the cell membrane. Alter-
natively, in view of the high binding of LCM antibody to
the 25 kd band, the major portion of peripheral rac1
could be 25 kd suggesting higher expression of post-
translationally modified rac. If this were true, then
access to 21 kd would be lowered. This could lead to
weak fluorescence in stimulated CML PMNL. However,
unaltered rac1 distribution on stimulation indicated an
absence of significant changes in rac1 localization.
fMLP stimulated degradation of rhoA is slower in CML
PMNL
In the Western blots about 50% normal and 60% CML
samples showed a drop in rhoA levels at early time
points of fMLP stimulation, resulting in a 20% drop in
average rhoA levels. In normal, the drop gradually
increased to a significant level (Figure 2a) (Table 1a).
But in CML the decrease was statistically significant
only at 45 min of stimulation (Table 1a).
Higher rhoA expression in unstimulated CML PMNL,
as compared to that in normal PMNL, was not statisti-
cally significant. But on stimulation, differences between
the rhoA levels of the two populations increased gradu-
ally, resulting in significantally lower (2-3 folds) levels in
normal at later time points.
In FCM analysis of normal PMNL, at early time points
of stimulation mixed response was seen. Later, a major-
ity of the samples showed decrease in rhoA (Figure 2e,
Table 1b). In CML PMNL, about 50% samples showed a
drop in rhoA at early time points, but eventually showed
an increase. As a result, at the later time points, rhoA
levels in stimulated CML PMNL remained at par with
the basal level (Table 1b).
A comparison between normal and CML PMNL showed
that unstimulated normal PMNL as well as those during
early stimulation have higher rhoA expression. But, at 45
min of stimulation, the picture reversed. Though the trend
seen for rhoA expression was similar by Western blotting
and FCM, the latter did not yield significant differences.
Intracellular distribution of rhoA is comparable in normal
and CML PMNL
In the majority of samples, unstimulated normal and
CML PMNL showed cytoplasmic rhoA. In 20% normal
and 40%CML samples, unstimulated PMNL showed
rhoA in the peripheral region below the F-actin layer. In
both, rhoA distribution remained unaltered on fMLP
treatment. Changes in rhoA levels were similar to those
seen using FCM, and were not associated with morpho-
logical changes (Figure 3a).
Co-localization of F-actin with rhoA
In unstimulated and stimulated normal and CML
PMNL, peripherally concentrated F-actin did not co-
localize with rhoA, while most of the diffused cytoplas-
mic actin co-localized with rhoA (Figure 3a). This was
reflected in the lack of statistically significant differences
in the co-localization coefficient of unstimulated (0.63 ±
0.04) and fMLP-stimulated PMNL (0.63 ± 0.02). CML
PMNL showed lower co-localization coefficients as com-
pared to the normal (0.57 ± 0.02). Moreover, co-locali-
zation coefficients were more scattered in stimulated
C M LP M N L( r a n g e0 . 1 3-0 . 8 6 )t h a nt h a ti nn o r m a l
PMNL (range 0.29 - 0.86). Less than one values of aver-
age co-localization coefficients in normal and CML
PMNL further supported the observation of lack of
colocalization of major part of F-actin with rhoA. In
contrast to this, in normal and CML PMNL, all rhoA
was co-localized with F-actin.
Some variation was seen within the unstimulated nor-
mal population with respect to co-localization of F-actin
with rhoA. To group the majority of normal samples as
a tight population and to segregate samples that
behaved differently from the rest, a cut off percentage
(20 percentile) was applied. All the samples above the
cut off were considered as “normal” and all the samples
below the cut off were categorized as “non-normal”. The
percentage of samples behaving as non-normal was
similar under unstimulated and stimulated conditions
(Table 2).
To segregate CML samples from the normal samples,
t h es a m ec u to f fw a sa p p l i e dt ot h eC M LP M N L .I n
CML, under unstimulated conditions, 32% of the sam-
ples behaved as non-normal. On stimulation, the
Table 2 Distribution of samples according to co-
localization of F-actin with rhoA
fMLP Stimulation PMNL Sample Distribution
Non-normal Normal
Unstimulated Normal 14% 86%
CML 32% 68%
0.5 min Normal 14% 86%
CML 45% 55%
5 min Normal 14% 86%
CML 32% 68%
10 min Normal 21% 79%
CML 36% 64%
30 min Normal 14% 86%
CML 55% 45%
45 min Normal 21% 79%
CML 18% 82%
20% percentile is used as a cut off for defining the pattern of co-localization
of F-actin with rhoA in normal and CML PMNL, as “normal” and “non-normal”.
Values in bold and italics mark the increased “non-normal” population.
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to 55% at 0.5 min and 30 min of fMLP stimulation,
respectively (Table 2). Thus, 0.5 and 30 min of fMLP
stimulation appeared to be critical to differentiate
between normal and CML PMNL.
Ras and rhoA are critical GTPases in normal and CML
PMNL, respectively
GTPases play a key role in signal transduction, leading
to spatial and temporal organization of cytoskeleton
proteins, especially actin. In order to understand the sig-
nalling network of GTPases better and to see if the
change in expression of one GTPase had any correlation
with change in correlation of other GTPase or with F-
actin, bivariate correlation analysis was used. This analy-
sis enables to measure the strength of linear relationship
between variables. To further understand if the corre-
lated variables as determined by the bivariate correlation
were directly linked or whether they were indirectly
linked, partial correlation analysis was done. It was also
used to check if correlation between non-correlated
variables as determined by bivariate correlation was
masked due to other variables. Bivariate and partial cor-
relation analysis of the data indicated negative correla-
tion between G-actin and F-actin at 30 min of fMLP
stimulation in normal PMNL. Moreover, ras emerged as
the critical GTPase regulating expression of the rhoGT-
Pases - rhoA and rac1, and also of G-actin and F-actin
(Figure 3b). In CML PMNL, rhoA took a central place
in the GTPases involved in actin polymerization instead
of ras. In CML PMNL, constitutively active tyrosine
kinase, bcr-abl might be independently activating ras,
rhoA and rac1, even in the absence of an external sti-
mulus like fMLP. This probably resulted in absence of
ras control on the actin polymerization pathway and
established new direct links like rac1 - rhoA, F-actin -
rhoA and F-actin - ras (Figure 3b). RhoA also showed a
suppression effect. This altered regulation of GTPase-
rhoA might have led to deregulated actin polymerization
and thereby defects in various actin-dependent func-
tional events.
Besides morphology or motility pathway, dynamics of
actin plays crucial role in cell division. Hence, if our
conclusion of crucial role of rhoA in CML pathogenesis
is true then it should be reflected in proliferation of
CML cells. Since PMNL used in these studies are term-
inally differentiated cells, effect of rhoA on cell prolifera-
tion cannot be tested in these cells. But it needs to be
tested either in CML cell lines or mononuclear cells
from bone marrow of CML patients. Resistance to ima-
tinib, a bcr-abl tyrosine kinase inhibitor which is the
first line of CML chemotherapy is the major challenge
for CML in clinics. Hence, we have used imatinib sensi-
tive and resistant CML cell lines to validate our
conclusion derived from the above-mentioned studies in
CML PMNL.
K562 is a pluoripotent CML cell lines derived from
CML patient in blastic crisis and is sensitive to imatinib.
Another cell line chosen was BaF3/bcr-abl/T315I that
expresses the most common and most resistant bcr-abl
mutant. To test specificity of the hypothesis, HL-60, a
bcr-abl negative promyelocytic leukemic cell line was
used as a control. Since activation of rhoGTPases is
important for their functioning, activation of rhoA was
inhibited by using C3 exoenzyme from Clostridium
botulinum, a known specific inhibitor of rhoA activa-
tion. To test involvement of signalling molecules down-
stream of rhoA, Y27632 - an inhibitor of ROCKI kinase
was used. At transcription level, rhoA was targeted by
using validated antisense oligonuleotides (ASODN).
Inhibition of rhoA at the transcriptional level by using
phosphodiester ASODN (PO) and phosphorothioate
ASODN (PS) resulted in about 20 - 40% growth inhibi-
tion in K562 and BaF3/bcr-abl/T315I. Inhibitory effect
of PO decreased by 48 hours while, effect of PS was
comparatively long lasting. This differential effect could
be explained on the basis of longer half-life and higher
binding affinities of PS than PO. Though this inhibitory
effect on cell proliferation proves our hypothesis that
rhoA plays important role in CML pathogenesis, role of
activation of rhoA and subsequent signalling events
remains to be elucidated. When activation of rhoA and
downstream signalling via ROCK were inhibited by
treatment of cell lines with C3 exoenzyme and Y-27632,
respectively both resulted in distinct growth inhibition
in K562 and BaF3/bcr-abl/T315I, but not in HL-60 (Fig-
ure 4). Inhibition of K562 and BaF3/bcr-abl/T315I by
C3 exoenzyme and Y-27632 was significantly higher
than the solvent control and HL-60, suggesting that
rhoA pathway inhibitors specifically inhibited growth of
bcr-abl expressing cells. Moreover, higher inhibition of
imatinib resistant BaF3/bcr-abl/T315I than K562 by C3
exoenzyme suggested that rhoA could be a good thera-
peutic target in CML.
Discussion
To understand defective actin polymerization in CML,
studies were focused on the downstream signalling
molecules in the actin polymerization pathway. The pre-
sent study has clearly noted higher expression of rhoA
and rac1 in unstimulated and fMLP stimulated CML
PMNL. Higher expression of GTPases is likely to be
associated with higher expression of their active forms
[23]. On stimulation, the drop in rhoA was lower in
CML than that in normal. Isoprenoid substrates are
essential to post-translationally modify ras and rhoGT-
Pases [24]. Reduction of isoprenoid substrates induced
up-regulation of ras, rap1a, rhoA and rhoB due to
Molli et al. Molecular Cancer 2012, 11:16
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Page 8 of 13Figure 4 Effect of rhoA and ROCK inhibition on cell growth: Percent growth inhibition in HL60, K562 and BaF3/bcr-abl/T315I treated with -
A) PO against rhoA, B) PS against rhoA, for 24 and 48 hours and C) C3 exoenzyme and Y-27632, for 48 hours. * Indicates significantly higher
growth inhibition than the respective untreated cells and treated HL-60.
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protein degradation. A crisis in the isoprenoid substrate
levels probably decreases protein degradation [24]. In
view of this, reduced degradation of rhoA in stimulated
CML PMNL could be due to reduced levels of the iso-
prenoid substrate. The presence of high levels of rhoA
results in disruption of the actin cytoskeleton and
microtubules [25]. Lowered number of microtubules
[26] and F-actin [4,27] have been reported in CML
PMNL. Thus, consistently high levels of rhoA in CML
PMNL could explain the defects in cytoskeleton, cell
polarization and chemotaxis.
In normal PMNL, fMLP treatment led to a decrease in
rhoA and total actin levels and increase in ras and rac1b
levels. These resulted in actin polymerization, formation
of lamellipodia and subsequently in chemotaxis, phago-
cytosis, etc. In CML, kinetics of expression of ras, rac
and rhoA is altered. Since rac1 and rhoA regulate each
other, and rac1 must inhibit rhoA to exert its motility
related effects, it can be speculated that altered
dynamics of these GTPases in CML could result in
defective actin polymerization and subsequent actin-
dependent functions. Further studies on expression of
active-rhoGTPases may elucidate more distinctly, the
differences in normal and leukemic populations.
CML PMNL remain in circulation for a longer period
than the corresponding normal PMNL. Mechanism of
this longevity is not clearly understood. GTPases also
act as molecular switches controlling proliferation and
differentiation of cells [28,29]. Over expression or muta-
tion can make GTPases constitutively active, and may
result in dysregulated cell signalling and proliferation
[23]. Ras along with rac1 or rho has been implicated in
tumorigenesis [30] and cell transformation [31,32].
Aberrant activation of rhoGTPases per se promotes
uncontrolled proliferation, invasion and metastatic prop-
erties of tumor cells [33]. Over expression of rhoGT-
Pases has been reported in many cancers [34-38].
Alteration in rhoA levels has been correlated with
malignancy [39]. It is suggested that cancer is associated
with higher expression, rather than any mutations, of
rhoGTPases [29,37].
Rac1 and rho regulate cell cycle progression through
the G1 phase [40], and also regulate the expression of
growth-promoting genes like c-fos that are required for
cell cycle progression [41]. Significantly increased rac1
RNA and protein has been reported in patients with
aggressive breast cancer and oral squamous cell carci-
noma [20,42]. Over-expression of rac1 induces a strong
proliferative response in NIH3T3 [43]. Rac1 stimulates
transcription of cyclin D1 via PAK, thereby promoting
cell cycle progression through G1 [40]. RhoA facilitates
entry into S phase by degradation of the cyclin-depen-
dent kinase inhibitor p
27kip1 [44]. Additionally,
constitutively activated mutants of the rhoGTPases sti-
mulate DNA synthesis leading to cell cycle progression.
Hence, higher expression of rac1 and rhoA in CML
PMNL could be responsible for increased proliferation
of these cells.
In normal PMNL, ras appeared to be a critical GTPase
regulating the expression of other GTPases and actin.
But in CML PMNL, rhoA emerged as the critical
GTPase. This altered behavior of rhoA could be respon-
sible for the diseased state. Since the chimeric bcr-abl
gene has Dbl homology (DH) domain and wild type bcr
has racGAP domain, role of rac pathway in leukemogen-
esis was predicted and tested. For example, the onco-
genic tyrosine kinase bcr-abl has been shown to activate
rac via vav and active rac was shown to be important in
leukemogenesis [45]. DH domain of bcr-abl activates
NF-kB via P38 MAPK activation [46]. Up regulation of
rhoA gene and rhoA regulator LARG is reported in bcr-
abl expressing cell lines [47,48]. Sahay et al. have shown
that p210 bcr-abl can stimulate rhoA activation inde-
pendent of its tyrosine kinase activity via its DH domain
and inhibition of rhoGEF activity resulted in impairment
of transforming activity of p210 that is measured by
anchorage independent growth [49]. Role of rhoA in
amoeboid motility of p210 bcr-abl expressing cells was
demonstrated by Daubon et al. [50]. Unwin et al. have
shown effects of inhibitors of rho on growth and migra-
tion of bcr-abl positive cells [47,51]. Burthem et al have
shown that ROCK inhibitors Y-27632 and fasudil selec-
tively inhibited growth of CD34 positive CML progeni-
tor cells [52]. Recently, role of rhoGTPases in
heamtopoiesis and haemopathies including CML is well
reviewed by Mulloy et al [53]. But to our knowledge,
there are no reports in the clinical samples, collectively
illustrating expression of ras and rhoGTPases and corre-
lating to the structural event like polymerization of
actin. In the present report, effects of stimulation on
expression of these molecules are also studied. Probably,
this is the first report wherein rhoGTPase pathway is
systematically dissected in clinical samples, using various
experimental approaches and over-expression of rhoA is
reported in CML. In collective analysis of these para-
meters, a statistically significant model has emerged sug-
gesting that rhoA is the critical GTPase regulating
expression of other GTPases and actin in CML PMNL.
Specific growth inhibition of bcr-abl expressing cells by
rhoA and ROCK inhibitors and more inhibition of ima-
tinib resistant cell line by rhoA activation inhibitor than
ROCK inhibitor observed by us, supported our hypoth-
esis and identified rhoA as a potential target for the
development of therapeutic drugs. Ohmine et al. have
shown by microarray analyses that rhoA and ras p21
protein activator (RASAP) levels are increased in imati-
nib resistant KCL22 cell line [47]. These observations
Molli et al. Molecular Cancer 2012, 11:16
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T315I than K562.
Often, the regulatory molecules are predicted by
microarray studies on the basis of transcriptional up
regulation. However, the transcriptional changes need
not be always reflected at the translational levels. Pro-
teomics is another tool that is used to identify regula-
tory molecules. Our approach of dissecting defective
signalling pathway at the molecular and cellular level is
a kind of focused proteomics and cellomics. Hence, in
comparison to the predictions on the basis of microar-
ray or proteomics alone, hypothesis based on the statis-
tical analysis of the expression of the signalling
molecules per se in clinical samples is more likely to be
translated successfully in clinics.
Conclusions
To summarize, in CML PMNL expression and spatial
organization of GTPases - ras, rhoA and rac has altered,
probably leading to altered actin dynamics. Hence, the
altered actin dependent functions in PMNL could be a
result of altered GTPases. In correlation analysis, rhoA
has emerged as the key regulator in CML. Hence it was
hypothesized that rhoA is the crucial factor regulating
altered behaviour of CML cells. This hypothesis was
validated by studying effect of rho/ROCK pathway inhi-
bitors on imatinib sensitive and resistant CML cell lines.
In view of these results, rhoA is proposed as a therapeu-
tic target for CML.
Materials and methods
Reagents
Antibodies and kits were obtained from various sources
listed here: Anti-actin, anti-rac1, alkaline phosphatase con-
jugated anti-rat antibody and anti-rhoA [Santacruz Inc.,
Santacruz, CA, USA]; anti-H-ras [Oncogene, San Diego,
CA, USA]; enhanced chemiluminescence kit containing
alkaline phosphatase conjugated goat anti-rabbit antibody
(GAR-AP) [New England Biolabs Inc., Ipswich, MA,
USA]; Alexa 488-conjugated goat anti-mouse antibody
(GAM) [Molecular Probes, Carlsbad, CA, USA]; FITC
conjugated anti-ras and TRITC conjugated anti-rac1 [Bec-
ton Dickinson, Franklin Lakes, NJ, USA]; goat anti-mouse
antibody alkaline phosphatase conjugated (GAM-AP)
[Sigma, St. Louis, MO, USA] and cell counting kit-8
(CCK-8) [Dojindo Laboratories, Kumamoto, Japan].
Clinical samples and cell lines
After taking written consent, peripheral blood was col-
lected from healthy volunteers (control) and CML
patients in chronic phase; before commencement of
therapy and processed simultaneously. PMNL were
isolated on a ficoll-hypaque gradient [54] and immedi-
ately used for the experiments.
Bcr-abl expressing cell lines K562 and BaF3/bcr-abl/T315I
were used along with bcr-abl negative cell line HL-60, as a
control. The cell lines were maintained in RPMI 1640 con-
taining 1X AB-AM and 10% (v/v) fetal bovine serum, at
37°C in a humidified atmosphere containing 5% CO2.
PMNL stimulation
PMNL were stimulated at 37°C with 10
-8Mf M L Pf o r
various time durations. For Western blotting, cells were
quickly pelleted at 4°C and lysed in Laemmli’ss a m p l e
buffer containing CompleteTM protease inhibitor
[Roche, Mannheim, Germany]. For flow cytometric and
microscopic analysis, cells were fixed with paraformalde-
hyde. Unstimulated PMNL were used as control.
Western blotting
Lysates form one million cells were loaded on 16% SDS-
PAGE. After confirming equal protein loading by stain-
ing the blots, actin and GTPases were detected. Protein
band density was quantitated as mean area density,
using the software-Labwork.
Immunofluorescent staining
Fixed PMNL were permeabilized with Triton-X100 and
stained using FITC-anti-ras or TRITC-anti-rac or anti-rho
followed by Alexa 488-GAM. For F-actin staining, TRITC-
phalloidin was used [4]. The cells were analysed by FCM
using FACScalibur (Becton-Dickinson) and LCM
MRC1024 (Biorad) using Lasersharp software. A mini-
mum of 10,000 cells were analysed by FCM. The median
channel number was taken as a measure of fluorescence
intensity. To precisely study localization of the molecules,
Z-series images of 1 μm thickness were analysed by LCM.
Growth inhibition assay
Cell lines were treated with inhibitor of rhoA GTPase
activation - C3 exoenzyme (10 μg/ml), ROCK I inhibitor
- Y-27632 (10 μM) and ASODN targeted against rhoA
(1 μM). Cell proliferation was monitored at 24 and 48
hrs., by using CCK-8 assay [55]. Effect of treatment on
cell growth was expressed as percent growth inhibition.
Statistical analysis
Wilcoxon signed rank test was used to compare the
values within normal and CML samples. Mann-Whitney
test was used to compare normal with CML and K562
and BaF3/bcr-abl/T315I with HL-60. Bivariate and par-
tial correlation analyses were used to study the relation-
ship between all the parameters. p <0 . 0 5w a s
considered to be statistically significant.
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Additional file 1: Figure S1. H-ras localization in normal PMNL:
Middle Z planes and 3D LCM images showing distribution of H-ras in
unstimulated and fMLP stimulated (0.5, 5, 10, 30, 45 min) normal PMNL.
The central panel shows the corresponding transmission images of the
fluorescent images. For studying distribution of GTPases, ‘thermo1’ LUT
based on the fluorescence intensity was applied to all the fluorescence
images in this figure. Fluorescence intensity reflects the expression level
of the protein of interest. The pseudocolour code used was as follows:
Dark blue: extremely low level of expression; Light blue: low level of
expression; Yellow: moderate level of expression; Orange: high level of
expression; Red: extremely high level of expression.
Additional file 2: Figure S2. H-ras localization in CML PMNL: Middle
Z planes and 3D LCM images showing distribution of H-ras in
unstimulated and fMLP stimulated (0.5, 5, 10, 30, 45 min) CML PMNL. The
central panel shows the corresponding transmission images of the
fluorescent images. For studying distribution of GTPases, ‘thermo1’ LUT
based on the fluorescence intensity was applied to all the fluorescence
images in this figure. Fluorescence intensity reflects the expression level
of the protein of interest. The pseudocolour code used was as follows:
Dark blue: extremely low level of expression; Light blue: low level of
expression; Yellow: moderate level of expression; Orange: high level of
expression; Red: extremely high level of expression.
Additional file 3: Figure S3. Rac1 localization in normal PMNL:
Middle Z planes and 3D LCM images showing distribution of rac1 in
unstimulated and fMLP stimulated (0.5, 5, 10, 30, 45 min) normal PMNL.
The central panel shows the corresponding transmission images of the
fluorescent images. For studying distribution of GTPases, ‘thermo1’ LUT
based on the fluorescence intensity was applied to all the fluorescence
images in this figure. Fluorescence intensity reflects the expression level
of the protein of interest. The pseudocolour code used was as follows:
Dark blue: extremely low level of expression; Light blue: low level of
expression; Yellow: moderate level of expression; Orange: high level of
expression; Red: extremely high level of expression.
Additional file 4: Figure S4. Rac1 localization in CML PMNL: Middle Z
planes and 3D LCM images showing distribution of rac1 in unstimulated
and fMLP stimulated (0.5, 5, 10, 30, 45 min) CML PMNL. The central panel
shows the corresponding transmission images of the fluorescent images.
For studying distribution of GTPases, ‘thermo1’ LUT based on the
fluorescence intensity was applied to all the fluorescence images in this
figure. Fluorescence intensity reflects the expression level of the protein
of interest. The pseudocolour code used was as follows: Dark blue:
extremely low level of expression; Light blue: low level of expression;
Yellow: moderate level of expression; Orange: high level of expression;
Red: extremely high level of expression.
Abbreviations
CCK-8: Cell counting kit-8; CML: chronic myeloid leukemia; FCM: flow
cytometry; fMLP: n-formyl-Methionyl-Leucyl-Phenyl alanine; LCM: laser
scanning confocal microscope; PKC: protein kinase C; PMNL:
Polymorphonuclear leucocytes.
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